Suppr超能文献

FOXA1 重编程决定 ESR1 突变型乳腺癌的视黄酸 X 受体反应。

FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.

机构信息

School of Medicine, Tsinghua University, Beijing, China.

Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Women's Research Institute, Pittsburgh, Pennsylvania.

出版信息

Mol Cancer Res. 2023 Jun 1;21(6):591-604. doi: 10.1158/1541-7786.MCR-22-0516.

Abstract

UNLABELLED

Estrogen receptor alpha (ER/ESR1) mutations occur in 30% to 40% of endocrine resistant ER-positive (ER+) breast cancer. Forkhead box A1 (FOXA1) is a key pioneer factor mediating ER-chromatin interactions and endocrine response in ER+ breast cancer, but its role in ESR1-mutant breast cancer remains unclear. Our previous FOXA1 chromatin immunoprecipitation sequencing (ChIP-seq) identified a large portion of redistributed binding sites in T47D genome-edited Y537S and D538G ESR1-mutant cells. Here, we further integrated FOXA1 genomic binding profile with the isogenic ER cistrome, accessible genome, and transcriptome data of T47D cell model. FOXA1 redistribution was significantly associated with transcriptomic alterations caused by ESR1 mutations. Furthermore, in ESR1-mutant cells, FOXA1-binding sites less frequently overlapped with ER, and differential gene expression was less associated with the canonical FOXA1-ER axis. Motif analysis revealed a unique enrichment of retinoid X receptor (RXR) motifs in FOXA1-binding sites of ESR1-mutant cells. Consistently, ESR1-mutant cells were more sensitive to growth stimulation with the RXR agonist LG268. The mutant-specific response was dependent on two RXR isoforms, RXR-α and RXR-β, with a stronger dependency on the latter. In addition, T3, the agonist of thyroid receptor (TR) also showed a similar growth-promoting effect in ESR1-mutant cells. Importantly, RXR antagonist HX531 blocked growth of ESR1-mutant cells and a patient-derived xenograft (PDX)-derived organoid with an ESR1 D538G mutation. Collectively, our data support the evidence for a stronger RXR response associated with FOXA1 reprograming in ESR1-mutant cells, suggesting development of therapeutic strategies targeting RXR pathways in breast tumors with ESR1 mutation.

IMPLICATIONS

It provides comprehensive characterization of the role of FOXA1 in ESR1-mutant breast cancer and potential therapeutic strategy through blocking RXR activation.

摘要

未加标签

雌激素受体 alpha(ER/ESR1)突变发生在 30%至 40%的内分泌抵抗型 ER 阳性(ER+)乳腺癌中。叉头框蛋白 A1(FOXA1)是一种关键的先驱因子,介导 ER+乳腺癌中的 ER-染色质相互作用和内分泌反应,但它在 ESR1 突变型乳腺癌中的作用尚不清楚。我们之前的 FOXA1 染色质免疫沉淀测序(ChIP-seq)在 T47D 基因组编辑的 Y537S 和 D538G ESR1 突变细胞中鉴定出大量重新分布的结合位点。在这里,我们进一步整合了 FOXA1 基因组结合图谱与 T47D 细胞模型的同基因 ER 顺式作用元件、可及基因组和转录组数据。FOXA1 的重分布与 ESR1 突变引起的转录组改变显著相关。此外,在 ESR1 突变细胞中,FOXA1 结合位点与 ER 的重叠频率较低,差异基因表达与典型的 FOXA1-ER 轴的相关性较低。基序分析显示,在 ESR1 突变细胞的 FOXA1 结合位点中,独特的视黄酸 X 受体(RXR)基序富集。一致地,ESR1 突变细胞对 RXR 激动剂 LG268 的生长刺激更敏感。突变特异性反应依赖于两种 RXR 异构体,RXR-α和 RXR-β,后者的依赖性更强。此外,甲状腺受体(TR)激动剂 T3 也在 ESR1 突变细胞中表现出类似的促生长作用。重要的是,RXR 拮抗剂 HX531 阻断了 ESR1 突变细胞和携带 ESR1 D538G 突变的患者来源异种移植(PDX)衍生类器官的生长。总的来说,我们的数据支持在 ESR1 突变细胞中,FOXA1 重编程与更强的 RXR 反应相关的证据,并表明针对具有 ESR1 突变的乳腺癌中 RXR 途径的治疗策略的发展。

启示

它通过阻断 RXR 激活,为 ESR1 突变型乳腺癌中 FOXA1 的作用提供了全面的特征描述,并提供了潜在的治疗策略。

相似文献

引用本文的文献

本文引用的文献

6
Hormonal modulation of ESR1 mutant metastasis.雌激素受体 1 突变体转移的激素调节。
Oncogene. 2021 Feb;40(5):997-1011. doi: 10.1038/s41388-020-01563-x. Epub 2020 Dec 15.
9
Overcoming Endocrine Resistance in Breast Cancer.克服乳腺癌内分泌耐药。
Cancer Cell. 2020 Apr 13;37(4):496-513. doi: 10.1016/j.ccell.2020.03.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验